

Zydus launches PEPAIR™, a first in India, affordable, drug-free, handheld device for better respiratory health

Ahmedabad, 17 February, 2026

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”), an innovation-led life-sciences company with an international presence, launches PEPAIR™, India’s first affordable Oscillating Positive Expiratory Pressure (OPEP) device featuring a 3-resistance system designed to help clear congestion and support effective mucous clearance and improve breathing in patients with COPD, Asthma, and Bronchiectasis. PEPAIR™ is an innovative, drug-free, handheld device with patented design. More than 90 lakh patients suffer from these chronic respiratory conditions in India. Chronic mucous hypersecretion is a common problem amongst these patients that requires an airway clearance solution for everyday care. PEPAIR™ is being launched in agreement with AeroDel Technology Innovations Pvt. Ltd, an Indian medical device company focused on simplifying inhalation through drug-delivery, pulmonary rehabilitation. In a patient-centric approach, Zydus offers PEPAIR™ at an affordable cost of Rs. 990 per unit.

Speaking on the launch, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said, “At Zydus, patient-centric innovation is about advancing healthcare in ways that make everyday care more accessible for patients. With PEPAIR™, India’s first affordable OPEP device, we are introducing a drug-free, handheld solution designed to support better breathing for patients with COPD, asthma and bronchiectasis. We look forward to expanding our efforts in advancing respiratory health through this launch”

OPEP, a therapy using a handheld, translucent device that creates pressure and vibrations during exhalation to loosen mucous, open airways, and promote clearance. PEPAIR™ contributes to clearing up impaired mucociliary pathways, removing airway obstruction, reducing cough and delivering optimal therapeutic response. OPEP-based airway clearance is recommended in established clinical guidance but in practice, limited affordability has restricted access for a large proportion of patients; an access gap PEPAIR™ aims to address.

Respiratory diseases are rising sharply in India due to a combination of extreme and persistent air pollution, climate-driven changes in allergens and ozone, rapid urbanisation, and delayed diagnosis of chronic lung conditions.

Zydus is one of India’s largest respiratory players, backed by a long legacy in oral and inhalation therapies. It leads the oral bronchodilator segment with Deriphyllin®, among India’s most prescribed methylxanthines. Building on this, Zydus offers an inhalation portfolio across Inhaled Corticosteroid



For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878



(ICS)+ Long-Acting Beta2-Agonist (LABA), LABA+ Long-Acting Muscarinic Antagonist (LAMA) and Single Inhaler Triple Therapy (SITT). It was first to introduce LABA+LAMA with Forglyn® and pioneered SITT with Forglyn® Plus. Innovation continued with once-daily triple therapies such as Odihale® G and Umiflo® Plus.

About Zydus Lifesciences Limited

Zydus Lifesciences Ltd., with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 29,000 people worldwide, including 1,500 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries. Over the last decade, Zydus has introduced several innovative, first-in class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals, and New Chemical Entities. For more details visit www.zyduslife.com

About AeroDel Technology Innovations Pvt. Ltd.

AeroDel is the innovator and developer of the underlying OPEP device platform for PEPAIR™ and the manufacturing partner for Zydus Lifesciences Ltd. The company develops and manufactures patient-centric respiratory devices designed for scale and affordability, with a focus on improving access to care in India and other global markets. AeroDel is supported by Venture Center (Entrepreneurship Development Center, Pune), the Department of Science and Technology, Government of India, AIC-CCMB, and the Startup India Seed Fund. For more details, visit www.aerodeltech.com.



For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878